Recently Added Drugs
1. Aqneursa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433862 | INTRABIO | NA |
Apr, 2037
(11 years from now) | |
| US12433863 | INTRABIO | NA |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2029 |
| Orphan Drug Exclusivity(ODE-498) | Sep 24, 2031 |
Drugs and Companies using LEVACETYLLEUCINE ingredient
NCE-1 date: 24 September, 2028
Market Authorisation Date: 24 September, 2024
Treatment: Treatment of neurological manifestations of niemann-pick disease type-c (npc) for a duration of greater than 3 months; Treatment of neurological manifestations of niemann-pick disease type-c (npc) for...
Dosage: FOR SUSPENSION
More Information on Dosage
AQNEURSA family patents
2. Augtyro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50634 | BRISTOL | NA |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| ODE*(ODE*) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-455) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-483) | Jun 13, 2031 |
| Orphan Drug Exclusivity(ODE-488) | Jun 13, 2031 |
Drugs and Companies using REPOTRECTINIB ingredient
NCE-1 date: 16 November, 2027
Market Authorisation Date: 15 November, 2023
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
AUGTYRO family patents
3. Clenpiq patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12458634 | FERRING PHARMS INC | NA |
Jan, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 15, 2021 |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of CLENPIQ before it's drug patent expiration?
More Information on Dosage
CLENPIQ family patents
4. Clotic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12246006 | CARWIN PHARM ASSOC | NA |
May, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 26, 2033 |
Drugs and Companies using CLOTRIMAZOLE ingredient
Market Authorisation Date: 26 September, 2025
Treatment: Treatment of fungal otic infection (fungal otitis externa, otomycosis) due to aspergillus species and candida species
Dosage: SOLUTION/DROPS
More Information on Dosage
CLOTIC family patents
5. Combogesic Iv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12220392 | HIKMA | NA |
Oct, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Method of treating moderate to severe pain (surgical) in adults as an adjunct to opioid analgesics
Dosage: SOLUTION
More Information on Dosage
COMBOGESIC IV family patents
6. Enbumyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260038 | CORSTASIS THERAP | NA |
Dec, 2040
(15 years from now) | |
| US12329731 | CORSTASIS THERAP | NA |
Dec, 2040
(15 years from now) | |
Drugs and Companies using BUMETANIDE ingredient
Market Authorisation Date: 12 September, 2025
Treatment: Intranasal bumetanide for the treatment of edema
Dosage: SPRAY
More Information on Dosage
ENBUMYST family patents
7. Fabhalta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12453726 | NOVARTIS | NA |
Jul, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-949) | Aug 07, 2027 |
| New Indication(I-963) | Mar 20, 2028 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: Treatment of paroxysmal noctural hemoglobinuria (pnh) by administration of 200 mg of iptacopan twice daily
Dosage: CAPSULE
More Information on Dosage
FABHALTA family patents
8. Forzinity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7576061 | STEALTH BIOTHERAPS | NA |
Jan, 2026
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083771 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11083772 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11771734 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US12268724 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US9687519 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2030 |
Drugs and Companies using ELAMIPRETIDE HYDROCHLORIDE ingredient
NCE-1 date: 19 September, 2029
Market Authorisation Date: 19 September, 2025
Treatment: Method for treating barth syndrome in adult and pediatric patients weighing at least 30kg
Dosage: SOLUTION
More Information on Dosage
FORZINITY family patents
9. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433906 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
|
US12433906 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Treating type 2 diabetes mellitus by assessing renal function, administering 10 empagliflozin if the egfr is >=30 ml/min/1.73 m2, and administering 25 mg empagliflozin if required for additional glyce...
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
10. Hetlioz Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12447141 | VANDA PHARMS INC | NA |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION
More Information on Dosage
HETLIOZ LQ family patents
11. Inluriyo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10654866 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| US11117902 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using IMLUNESTRANT TOSYLATE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Treatment: Treatment of adults with er-positive, her2-negative esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Dosage: TABLET
More Information on Dosage
INLURIYO family patents
12. Itovebi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12410189 | GENENTECH INC | NA |
Jun, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2029 |
Drugs and Companies using INAVOLISIB ingredient
NCE-1 date: 10 October, 2028
Market Authorisation Date: 10 October, 2024
Treatment: Combination with palbociclib and fulvestrant for treatment of adults with endocrine-resistant pik3ca-mutated hr-positive her2-negative locally advanced or metastatic breast cancer following recurrence...
Dosage: TABLET
More Information on Dosage
ITOVEBI family patents
13. Jardiance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427162 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US12433906 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
|
US12433906 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: Delaying loss of egfr or delaying progression to end-stage renal disease by administration of empagliflozin to patients with stage 2, 3, 4 or 5 chronic kidney disease; Treating type 2 diabetes mellitu...
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
14. Jascayd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754073 | BOEHRINGER INGELHEIM | NA |
Nov, 2029
(4 years from now) | |
| US8609670 | BOEHRINGER INGELHEIM | NA |
Aug, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9802954 | BOEHRINGER INGELHEIM | NA |
Feb, 2034
(8 years from now) | |
| US11406638 | BOEHRINGER INGELHEIM | NA |
Oct, 2038
(12 years from now) | |
| US11813266 | BOEHRINGER INGELHEIM | NA |
Oct, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2030 |
Drugs and Companies using NERANDOMILAST ingredient
NCE-1 date: 07 October, 2029
Market Authorisation Date: 07 October, 2025
Treatment: Treatment of idiopathic pulmonary fibrosis in adults; Treatment of idiopathic pulmonary fibrosis in adults in combination with nintedanib or a pharmaceutically acceptable salt thereof; Treatment of id...
Dosage: TABLET
More Information on Dosage
JASCAYD family patents
15. Javadin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233049 | AZURITY | NA |
Jul, 2042
(16 years from now) | |
| US12440474 | AZURITY | NA |
Jul, 2042
(16 years from now) | |
Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
JAVADIN family patents
16. Katerzia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383498 | AZURITY | NA |
Oct, 2037
(11 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage
KATERZIA family patents
17. Konvomep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12440566 | AZURITY | NA |
Jul, 2039
(13 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
KONVOMEP family patents
18. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12318390 | JANSSEN BIOTECH | NA |
Apr, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
19. Linzess patent expiration
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7304036 (Pediatric) | ABBVIE | NA |
Feb, 2027
(1 year, 3 months from now) | |
|
US8933030 (Pediatric) | ABBVIE | NA |
Aug, 2031
(5 years from now) | |
|
US10675325 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
|
US10702576 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
|
US8748573 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US8802628 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US9708371 (Pediatric) | ABBVIE | NA |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
20. Livtencity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433907 | TAKEDA PHARMS USA | NA |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: Treating post-transplant cmv infection/disease refractory to ganciclovir, valganciclovir, cidofovir or foscarnet by administering 1200 mg maribavir twice daily, where patient is exposed to/receiving a...
Dosage: TABLET
More Information on Dosage
LIVTENCITY family patents
21. Nextstellis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427114 | MAYNE PHARMA | NA |
Jun, 2036
(10 years from now) | |
| US12458649 | MAYNE PHARMA | NA |
Oct, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 15 April, 2025
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET
More Information on Dosage
NEXTSTELLIS family patents
22. Norliqva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12440441 | CMP DEV LLC | NA |
Feb, 2041
(15 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the symptomatic treatment of chronic stable angina
Dosage: SOLUTION
More Information on Dosage
NORLIQVA family patents
23. Olpruva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154521 | ACER | Palatable compositions including sodium phenylbutyrate and uses thereof |
Oct, 2036
(10 years from now) | |
| US11433041 | ACER | Palatable compositions including sodium phenylbutyrate and uses thereof |
Oct, 2036
(10 years from now) | |
Drugs and Companies using SODIUM PHENYLBUTYRATE ingredient
Market Authorisation Date: 10 October, 2025
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
OLPRUVA family patents
24. Opfolda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12419937 | AMICUS THERAP US | NA |
Mar, 2033
(7 years from now) | |
| US12414985 | AMICUS THERAP US | NA |
Dec, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE
More Information on Dosage
OPFOLDA family patents
25. Otezla Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427136 | AMGEN INC | NA |
May, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jul 19, 2026 |
| M(M-299) | Jul 20, 2026 |
| Pediatric Exclusivity(PED) | Jan 20, 2027 |
Drugs and Companies using APREMILAST ingredient
Market Authorisation Date: 29 August, 2025
Treatment: Treatment of psoriatic arthritis
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OTEZLA XR family patents
26. Palsonify patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10351547 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10597377 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US11414397 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US9896432 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10464918 | CRINETICS | NA |
Jan, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10875839 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US11266641 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US11957674 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US12208092 | CRINETICS | NA |
Mar, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using PALTUSOTINE HYDROCHLORIDE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Treatment: Treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option; Treatment of adults with acromegaly who have hepatic impairment and an inadequat...
Dosage: TABLET
More Information on Dosage
PALSONIFY family patents
27. Phyrago patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433891 | HANDA THERAP | NA |
Jan, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-307) | Dec 05, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 05 December, 2023
Treatment: Use of dasatinib for treatment of newly diagnosed adults with ph+ cml in chronic phase, when coadministered with a gastric acid reducing agent
Dosage: TABLET
More Information on Dosage
PHYRAGO family patents
28. Posluma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427207 | BLUE EARTH | NA |
Nov, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
POSLUMA family patents
29. Purified Cortrophin Gel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12440542 | ANI PHARMS | NA |
Oct, 2043
(17 years from now) | |
Drugs and Companies using CORTICOTROPIN ingredient
Market Authorisation Date: 01 January, 1982
Treatment: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
Dosage: INJECTABLE
More Information on Dosage
PURIFIED CORTROPHIN GEL family patents
30. Rhapsido patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512084 | NOVARTIS | NA |
Nov, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10457647 | NOVARTIS | NA |
Nov, 2034
(8 years from now) | |
| US12419889 | NOVARTIS | NA |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2030 |
Drugs and Companies using REMIBRUTINIB ingredient
NCE-1 date: 30 September, 2029
Market Authorisation Date: 30 September, 2025
Treatment: Treatment of chronic autoimmune urticaria; Treatment of chronic spontaneous urticaria
Dosage: TABLET
More Information on Dosage
RHAPSIDO family patents
31. Rocuronium Bromide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11998605 | STERINOVA INC | NA |
Jul, 2039
(13 years from now) | |
Drugs and Companies using ROCURONIUM BROMIDE ingredient
Market Authorisation Date: 24 October, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ROCURONIUM BROMIDE family patents
32. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12447149 | DECIPHERA PHARMS | NA |
Dec, 2044
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
33. Rytelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12442000 | GERON | NA |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia
Dosage: POWDER
More Information on Dosage
RYTELO family patents
34. Suflave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433914 | BRAINTREE LABS | NA |
Jun, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 15, 2026 |
Market Authorisation Date: 15 June, 2023
Treatment: Gastrointestinal flavored solution indicated for cleansing the colon in preparation for colonoscopy
Dosage: FOR SOLUTION
More Information on Dosage
SUFLAVE family patents
35. Syfovre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12458695 | APELLIS PHARMS | NA |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SYFOVRE family patents
36. Sympazan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12290597 | ASSERTIO SPECLTY | NA |
Sep, 2039
(13 years from now) | |
| US12403090 | ASSERTIO SPECLTY | NA |
Sep, 2039
(13 years from now) | |
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: Method of treating seizures
Dosage: FILM
More Information on Dosage
SYMPAZAN family patents
37. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427162 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US12433906 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
|
US12433906 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: Delaying loss of egfr or delaying progression to end-stage renal disease by administration of empagliflozin to patients with stage 2, 3, 4 or 5 chronic kidney disease; Treating type 2 diabetes mellitu...
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
38. Synjardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427162 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US12433906 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
|
US12433906 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: Delaying loss of egfr or delaying progression to end-stage renal disease by administration of empagliflozin to patients with stage 2, 3, 4 or 5 chronic kidney disease; Treating type 2 diabetes mellitu...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage
SYNJARDY XR family patents
39. Tpoxx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433868 | SIGA TECHNOLOGIES | NA |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 13 July, 2018
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TPOXX family patents
40. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12458632 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US12458633 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
41. Vasopressin In Sodium Chloride 0.9% patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12447190 | BAXTER HLTHCARE CORP | NA |
Sep, 2044
(18 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 29 September, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VASOPRESSIN IN SODIUM CHLORIDE 0.9% family patents
42. Vijoice patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427141 | NOVARTIS | NA |
Feb, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: Treatment of severe phosphatidylinositol-3-kinase catalytic subunit alpha (pik3ca)-related overgrowth spectrum (pros) having an overgrowth of multiple tissues, that requires systemic therapy
Dosage: TABLET; GRANULES
More Information on Dosage
VIJOICE family patents
43. Voranigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433895 | SERVIER | NA |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2029 |
| Orphan Drug Exclusivity(ODE-491) | Aug 06, 2031 |
Drugs and Companies using VORASIDENIB ingredient
NCE-1 date: 06 August, 2028
Market Authorisation Date: 06 August, 2024
Treatment: A method of treating a cancer characterized by an idh1 mutation following surgery, wherein the cancer is grade 2 astrocytoma or oligodendroglioma
Dosage: TABLET
More Information on Dosage
VORANIGO family patents
44. Xipere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12419833 | BAUSCH AND LOMB INC | NA |
Apr, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION
More Information on Dosage
XIPERE family patents
45. Yorvipath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12453778 | ASCENDIS PHARMA BONE | NA |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Treatment: Treatment of hypoparathyroidism in adults
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
46. Zepzelca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433890 | JAZZ | NA |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 15 June, 2024
Market Authorisation Date: 15 June, 2020
Treatment: Treating metastatic sclc after platinum chemotherapy with lurbinectedin monotherapy by reducing the dose for grade 4 or any grade febrile neutropenia from 3.2 to 2.6 mg/m2 and 2.6 to 2.0 mg/m2 lurbine...
Dosage: POWDER
More Information on Dosage
ZEPZELCA family patents
47. Zolymbus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314780 | THEA PHARMA | NA |
Jun, 2036
(10 years from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 09 September, 2025
Treatment: A method of treating a patient with glaucoma or ocular hypertension
Dosage: GEL
More Information on Dosage
ZOLYMBUS family patents
48. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(11 years from now) | |
| US11793796 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(11 years from now) | |
| US11819496 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(11 years from now) | |
| US11992480 | ARCUTIS | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
Jun, 2037
(11 years from now) | |
| US12005051 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Jun, 2037
(11 years from now) | |
| US12005052 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(11 years from now) | |
| US12011437 | ARCUTIS | Roflumilast formulations with an improved pharmacokinetic profile |
Jun, 2037
(11 years from now) | |
| US12016848 | ARCUTIS | Roflumilast formulations with an improved pharmacokinetic profile |
Jun, 2037
(11 years from now) | |
| US12042487 | ARCUTIS | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
Jun, 2037
(11 years from now) | |
| US12220409 | ARCUTIS | Roflumilast formulations with an improved pharmacokinetic profile |
Jun, 2037
(11 years from now) | |
| US12257242 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(11 years from now) | |
| US12310956 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(11 years from now) | |
| US12336983 | ARCUTIS | NA |
Jun, 2037
(11 years from now) | |
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(11 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(11 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Oct 04, 2028 |
| New Indication(I-969) | May 22, 2028 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 09 July, 2024
Treatment: Topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age
Dosage: CREAM
More Information on Dosage
ZORYVE family patents
49. Ztalmy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12115169 | MARINUS | NA |
Sep, 2042
(16 years from now) | |
| US12268696 | MARINUS | NA |
Sep, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
| Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION
More Information on Dosage
ZTALMY family patents
50. Zusduri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12440568 | UROGEN PHARMA | NA |
Jan, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 12, 2028 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 12 June, 2025
Treatment: Treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Dosage: POWDER
More Information on Dosage
ZUSDURI family patents